Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 590 matching trials from the live ClinicalTrials.gov search.
Filters: "T2DM" Condition: Type 2 Diabetes Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes

NCT00678080
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Metformin, Insulin (NPH and Regular)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Brownsville, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional

Examining The Role of CGM in T2DM

NCT01614262
View directory record Official record
Conditions
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions
Continuous Glucose Monitoring with treatment algorithm
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 30, 2026, 7:23 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canakinumab, Metformin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pre Post Evaluation of Temperature, Steps, and Glucose With Additional Time Spent Outdoors in an Urban and Rural Setting

NCT03614780
View directory record Official record
Conditions
Temperature, Exercise, Diabetes Mellitus, Type 2
Interventions
30 minutes outdoors
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
19 Years to 65 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 30, 2026, 7:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Dietary Guidelines 3 Diet Patterns Study (DG3D): Phase 2

NCT05254496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Dietary Intervention Classes
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 1 Interventional

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT04143802
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3437943, Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Lenexa, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 1 Interventional

CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

NCT04990427
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
CLBS201
Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting Early Phase 1 Interventional

Type 2 Diabetes and Blood Brain Barrier Improvement

NCT06322212
View directory record Official record
Conditions
Type2diabetes
Interventions
Thiamine, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting Not applicable Interventional

OASIS: Peer Support for T2DM in Appalachia (Peer Coaches)

NCT06003634
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Peer Coaching - Peer Participants A, Peer Coaching - Peer Participants B, Peer Coaching - Peer Participants C, Peer Coaching - Peer Participants D
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bowling Green, Kentucky • Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

NCT01221545
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

NCT01119846
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

NCT06305351
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus (T2DM)
Interventions
K-757 and K-833 QD, K-757 and K-833 BID, Matching placebo to K-757 and K-833 QD, Matching placebo to K-757 and K-833 BID
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional

A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

NCT02836574
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Renal Autologous Cell Therapy (REACT), Renal Biopsy
Biological · Procedure
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers

NCT00501397
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
ketoconazole, GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional

Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.

NCT06810726
View directory record Official record
Conditions
Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer, Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), Chronic Wound Care
Interventions
Platelet Rich Plasma
Device
Lead sponsor
Estar Medical dba Medical Technologies, LTD
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting Not applicable Interventional

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

NCT06906640
View directory record Official record
Conditions
Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
Interventions
(IRIS-CKD Management Program): Education, (IRIS-CKD Management Program): GDMT
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

NCT00918138
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Metformin XR, Placebo matching Metformin XR, Placebo matching Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Redlands, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional Results available

Changing Health Through Food Support for Diabetes

NCT04959487
View directory record Official record
Conditions
Type 2 Diabetes, Food Insecurity
Interventions
Food support, Nutritional Counseling and education
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

NCT03954834
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Huntington Park, California • Los Angeles, California • Montclair, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

NCT04501406
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

NCT05409027
View directory record Official record
Conditions
Type 2 Diabetes Mellitus in Obese, Obesity, Type2Diabetes
Interventions
SPI-62, Cortisone-d8
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

NCT00770081
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
vildagliptin, sitagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Sep 30, 2026, 7:23 PM EDT